Financial Ratios Guardant Health, Inc.
Equities
GH
US40131M1099
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 101.85 USD | +3.55% |
|
-10.69% | -0.28% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
Profitability | |||||||||
Return on Assets | -9.48 | -11.48 | -17.84 | -17.64 | -16.95 | ||||
Return on Total Capital | -9.89 | -12.15 | -19.73 | -20.36 | -20.47 | ||||
Return On Equity % | -22.35 | -38.47 | -185.65 | -438.12 | -4.58K | ||||
Return on Common Equity | -24.21 | -41.75 | -185.65 | -438.12 | -4.58K | ||||
Margin Analysis | |||||||||
Gross Profit Margin % | 67.73 | 67.11 | 65.23 | 59.74 | 60.79 | ||||
SG&A Margin | 103.96 | 106.66 | 103.17 | 79.98 | 73.75 | ||||
EBITDA Margin % | -79.93 | -104.04 | -113.1 | -77.37 | -54.29 | ||||
EBITA Margin % | -84.06 | -109.49 | -120.54 | -84.5 | -59.73 | ||||
EBIT Margin % | -85.53 | -110 | -121.1 | -84.98 | -60.02 | ||||
Income From Continuing Operations Margin % | -85.89 | -102.98 | -145.61 | -85.02 | -59.05 | ||||
Net Income Margin % | -88.51 | -108.57 | -145.61 | -85.02 | -59.05 | ||||
Net Avail. For Common Margin % | -88.51 | -108.57 | -145.61 | -85.02 | -59.05 | ||||
Normalized Net Income Margin | -54.49 | -74.08 | -89.03 | -49.2 | -33.04 | ||||
Levered Free Cash Flow Margin | -24.33 | -33.05 | -65.75 | -31.36 | -19.87 | ||||
Unlevered Free Cash Flow Margin | -24.94 | -33.3 | -65.96 | -31.54 | -20 | ||||
Asset Turnover | |||||||||
Asset Turnover | 0.18 | 0.17 | 0.24 | 0.33 | 0.45 | ||||
Fixed Assets Turnover | 3.32 | 1.8 | 1.37 | 1.75 | 2.54 | ||||
Receivables Turnover (Average Receivables) | 5.66 | 4.95 | 4.61 | 6.06 | 7.43 | ||||
Inventory Turnover (Average Inventory) | 4.88 | 4.6 | 3.8 | 4 | 4.36 | ||||
Short Term Liquidity | |||||||||
Current Ratio | 28.27 | 5.72 | 6.17 | 6.54 | 4.68 | ||||
Quick Ratio | 27.66 | 5.29 | 5.74 | 6.11 | 4.21 | ||||
Operating Cash Flow to Current Liabilities | -1.56 | -1.07 | -1.6 | -1.58 | -1.06 | ||||
Days Sales Outstanding (Average Receivables) | 64.64 | 73.73 | 79.13 | 60.2 | 49.29 | ||||
Days Outstanding Inventory (Average Inventory) | 74.95 | 79.27 | 96.05 | 91.27 | 84.01 | ||||
Average Days Payable Outstanding | 43.04 | 34.75 | 110.61 | 92.75 | 55.27 | ||||
Cash Conversion Cycle (Average Days) | 96.55 | 118.25 | 64.56 | 58.72 | 78.02 | ||||
Long Term Solvency | |||||||||
Total Debt/Equity | 63.03 | 212.98 | 2.28K | 853.12 | -956.74 | ||||
Total Debt / Total Capital | 38.66 | 68.05 | 95.79 | 89.51 | 111.67 | ||||
LT Debt/Equity | 62.54 | 210.99 | 2.24K | 835.51 | -935.82 | ||||
Long-Term Debt / Total Capital | 38.36 | 67.41 | 94.26 | 87.66 | 109.23 | ||||
Total Liabilities / Total Assets | 40.33 | 70.74 | 96.26 | 91.12 | 109.4 | ||||
EBIT / Interest Expense | -51.46 | -159.49 | -211.24 | -185.89 | -171.87 | ||||
EBITDA / Interest Expense | -46.91 | -141.26 | -186.19 | -157.74 | -143.4 | ||||
(EBITDA - Capex) / Interest Expense | -54.5 | -170.38 | -216.25 | -165.68 | -156.99 | ||||
Total Debt / EBITDA | -3.82 | -3.77 | -2.85 | -3.33 | -3.61 | ||||
Net Debt / EBITDA | 5.31 | 0.71 | -0.75 | -0.46 | -1.34 | ||||
Total Debt / (EBITDA - Capex) | -3.29 | -3.13 | -2.46 | -3.17 | -3.3 | ||||
Net Debt / (EBITDA - Capex) | 4.57 | 0.59 | -0.64 | -0.43 | -1.22 | ||||
Growth Over Prior Year | |||||||||
Total Revenues, 1 Yr. Growth % | 33.75 | 30.32 | 20.31 | 25.45 | 31.04 | ||||
Gross Profit, 1 Yr. Growth % | 35.18 | 29.12 | 16.94 | 14.9 | 33.34 | ||||
EBITDA, 1 Yr. Growth % | 224.9 | 62.73 | 30.79 | -13.29 | -8.49 | ||||
EBITA, 1 Yr. Growth % | 202.88 | 61.6 | 32.46 | -11.21 | -7.78 | ||||
EBIT, 1 Yr. Growth % | 199.26 | 61.21 | 32.45 | -11.12 | -7.84 | ||||
Earnings From Cont. Operations, 1 Yr. Growth % | 262.98 | 56.23 | 70.12 | -26.76 | -8.98 | ||||
Net Income, 1 Yr. Growth % | 235.47 | 59.85 | 61.36 | -26.76 | -8.98 | ||||
Normalized Net Income, 1 Yr. Growth % | 205.69 | 70.54 | 44.58 | -30.11 | -12.41 | ||||
Diluted EPS Before Extra, 1 Yr. Growth % | 211.7 | 53.84 | 60 | -33.17 | -16.96 | ||||
Accounts Receivable, 1 Yr. Growth % | 11.07 | 83.22 | -0.41 | -8.71 | 24.18 | ||||
Inventory, 1 Yr. Growth % | 49.63 | 35.03 | 68.21 | 20.06 | 14.75 | ||||
Net Property, Plant and Equip., 1 Yr. Growth % | 37.52 | 213.51 | 8.93 | -11.47 | -7.81 | ||||
Total Assets, 1 Yr. Growth % | 136.02 | -2.96 | -26.97 | 10.96 | -16.84 | ||||
Tangible Book Value, 1 Yr. Growth % | 64.04 | -50.94 | -92.8 | 224.19 | -202.24 | ||||
Common Equity, 1 Yr. Growth % | 62.64 | -50.33 | -90.67 | 163.68 | -188 | ||||
Cash From Operations, 1 Yr. Growth % | 120.49 | 101.12 | 48.06 | 5.01 | -26.19 | ||||
Capital Expenditures, 1 Yr. Growth % | 93.26 | 107.43 | 3.23 | -73.55 | 71.26 | ||||
Levered Free Cash Flow, 1 Yr. Growth % | 37.43 | 62.87 | 139.36 | -39.49 | -17.6 | ||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 42.96 | 60.42 | 138.3 | -39.36 | -17.51 | ||||
Compound Annual Growth Rate Over Two Years | |||||||||
Total Revenues, 2 Yr. CAGR % | 77.86 | 32.02 | 25.21 | 22.85 | 28.22 | ||||
Gross Profit, 2 Yr. CAGR % | 102.35 | 32.12 | 22.88 | 15.91 | 23.78 | ||||
EBITDA, 2 Yr. CAGR % | 63.43 | 134.05 | 45.89 | 5.95 | -11.17 | ||||
EBITA, 2 Yr. CAGR % | 61.82 | 123.81 | 46.31 | 7.93 | -9.75 | ||||
EBIT, 2 Yr. CAGR % | 62.44 | 123.37 | 46.12 | 7.98 | -9.73 | ||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 70.96 | 138.13 | 63.03 | 11.63 | -18.35 | ||||
Net Income, 2 Yr. CAGR % | 72.73 | 131.57 | 60.6 | 8.71 | -18.35 | ||||
Normalized Net Income, 2 Yr. CAGR % | 66.89 | 132.12 | 57.57 | 0.11 | -21.89 | ||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -3.55 | 118.98 | 56.89 | 3.4 | -25.51 | ||||
Accounts Receivable, 2 Yr. CAGR % | 22.2 | 42.65 | 35.08 | -4.65 | 6.47 | ||||
Inventory, 2 Yr. CAGR % | 57.68 | 42.15 | 50.71 | 42.11 | 17.37 | ||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 79.71 | 107.64 | 84.8 | -1.8 | -9.66 | ||||
Total Assets, 2 Yr. CAGR % | 96.66 | 51.34 | -15.82 | -9.98 | -3.94 | ||||
Tangible Book Value, 2 Yr. CAGR % | 64.03 | -10.29 | -81.21 | -51.7 | 82.06 | ||||
Common Equity, 2 Yr. CAGR % | 63.94 | -10.12 | -78.47 | -50.4 | 52.33 | ||||
Cash From Operations, 2 Yr. CAGR % | 19.99 | 110.58 | 72.56 | 24.69 | -11.96 | ||||
Capital Expenditures, 2 Yr. CAGR % | 33.81 | 100.22 | 46.34 | -47.75 | -32.7 | ||||
Levered Free Cash Flow, 2 Yr. CAGR % | 2.81 | 55.58 | 97.44 | 19.69 | -29.52 | ||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 4.72 | 57.32 | 95.52 | 19.55 | -29.4 | ||||
Compound Annual Growth Rate Over Three Years | |||||||||
Total Revenues, 3 Yr. CAGR % | 79.18 | 60.34 | 28 | 25.29 | 25.52 | ||||
Gross Profit, 3 Yr. CAGR % | 120.06 | 74.2 | 26.85 | 20.16 | 21.45 | ||||
EBITDA, 3 Yr. CAGR % | 49.63 | 65.47 | 92.78 | 22.24 | 1.06 | ||||
EBITA, 3 Yr. CAGR % | 48.49 | 64.42 | 87.91 | 23.47 | 2.56 | ||||
EBIT, 3 Yr. CAGR % | 49.35 | 64.14 | 87.66 | 23.41 | 2.58 | ||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 43.57 | 65.9 | 112.88 | 24.86 | 4.28 | ||||
Net Income, 3 Yr. CAGR % | 45.01 | 68.32 | 105.3 | 23.62 | 2.46 | ||||
Normalized Net Income, 3 Yr. CAGR % | 49.29 | 70.25 | 98.23 | 19.84 | -4.1 | ||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -28.34 | 12.69 | 97.23 | 18.04 | -3.89 | ||||
Accounts Receivable, 3 Yr. CAGR % | 60.93 | 39.87 | 26.55 | 18.54 | 4.13 | ||||
Inventory, 3 Yr. CAGR % | 46.08 | 49.74 | 50.35 | 39.71 | 32.33 | ||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 84.14 | 116.34 | 67.46 | 44.6 | -3.84 | ||||
Total Assets, 3 Yr. CAGR % | 87.81 | 55.4 | 18.7 | -7.7 | -12.33 | ||||
Tangible Book Value, 3 Yr. CAGR % | 85.58 | 9.7 | -61.31 | -51.45 | -37.98 | ||||
Common Equity, 3 Yr. CAGR % | 89.32 | 10.11 | -57.76 | -50.38 | -39.95 | ||||
Cash From Operations, 3 Yr. CAGR % | 12.89 | 42.53 | 87.25 | 46.23 | 4.69 | ||||
Capital Expenditures, 3 Yr. CAGR % | 75.6 | 54.86 | 60.55 | -17.26 | -22.38 | ||||
Levered Free Cash Flow, 3 Yr. CAGR % | 7.4 | 23.23 | 79.6 | 32.63 | 5.94 | ||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 9.4 | 24.04 | 80.67 | 31.86 | 5.9 | ||||
Compound Annual Growth Rate Over Five Years | |||||||||
Total Revenues, 5 Yr. CAGR % | - | 71.41 | 55.25 | 44.14 | 28.08 | ||||
Gross Profit, 5 Yr. CAGR % | - | 140.37 | 74.3 | 48.01 | 25.61 | ||||
EBITDA, 5 Yr. CAGR % | - | 57.46 | 49.36 | 38.44 | 41.41 | ||||
EBITA, 5 Yr. CAGR % | - | 56.31 | 49.07 | 38.94 | 40.14 | ||||
EBIT, 5 Yr. CAGR % | - | 56.45 | 49.21 | 38.82 | 40.04 | ||||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | 52.84 | 51.06 | 41.59 | 45.1 | ||||
Net Income, 5 Yr. CAGR % | - | 54.46 | 51.06 | 41.32 | 41.97 | ||||
Normalized Net Income, 5 Yr. CAGR % | - | 57.2 | 53.5 | 37.67 | 36.58 | ||||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | 2.52 | -1.96 | 8.88 | 33.61 | ||||
Accounts Receivable, 5 Yr. CAGR % | - | 94.65 | 50.05 | 19.99 | 18.1 | ||||
Inventory, 5 Yr. CAGR % | - | 61.77 | 47.92 | 46.64 | 36.17 | ||||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | 90.13 | 84.4 | 57.73 | 30.83 | ||||
Total Assets, 5 Yr. CAGR % | - | 80.03 | 36.25 | 24.91 | 9.07 | ||||
Tangible Book Value, 5 Yr. CAGR % | - | 44.3 | -25.75 | -20.98 | -28.11 | ||||
Common Equity, 5 Yr. CAGR % | - | 45.09 | -20.66 | -19.96 | -29.44 | ||||
Cash From Operations, 5 Yr. CAGR % | - | 41.61 | 33.77 | 35.11 | 38.46 | ||||
Capital Expenditures, 5 Yr. CAGR % | - | 111.67 | 63.25 | 0.28 | 13.39 | ||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | 39.32 | 21.8 | 23.54 | ||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | 40.27 | 22.22 | 24.07 |
- Stock Market
- Equities
- GH Stock
- Financials Guardant Health, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















